Tradestie Institutional Equity Comparison Engine

CGEN vs EVGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CGEN trades at 12.4x Forward P/E with 41.3% operating margin (+102.1% YoY revenue) versus EVGN at N/M Forward P/E and -858.2% operating margin (-60.7% YoY). In options structure, CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro) against EVGN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
CGEN 12.4x vs EVGN N/M Fwd P/E
Growth & Margin Winner CGEN
Op Margin 41.3% vs -858.2% ยท YoY +102.1% vs -60.7%
Momentum & Technical Winner CGEN
1Y +23.2% vs -71.9% ยท 52W Pos 33% vs 9%
Options & Structure Winner CGEN
BREAKDOWN (57th %ile IV) vs UNCLASSIFIED (N/A IV)
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
EVGN NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
1M Return -7.58%
1Y Return -71.89%
Forward P/E N/M
Unified AI Score
41.2 / 100 SELL
Tech 25.0 Fund 48.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEN +23.17% EVGN -71.89% Spread: +95.06 pp (CGEN Lead)

Pillar 3 Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CGEN Revenue EVGN Revenue CGEN Op. Margin EVGN Op. Margin Margin Edge
Q3 '25 $10M $0M -417.4% -873.1% CGEN
Q4 '25 $270M $0M 83.2% -1659.9% CGEN
Q1 '26 $10M $0M -414.4% -943.1% CGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEN (10) vs EVGN (0)
Institutional Metric CGEN EVGN Criterion Row Winner
Market Capitalization Scale $193.2M $6.0M Larger Scale CGEN
Trailing P/E Ratio Valuation 5.2x N/M Lower Multiple CGEN
Forward P/E Ratio Valuation 12.4x N/M Lower Multiple CGEN
Revenue Growth (YoY) Growth +102.1% -60.7% Higher Growth CGEN
Operating Margin (TTM) Profitability 41.3% -858.2% Higher Margin CGEN
Net Profit Margin Profitability 47.9% 0.0% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency 57.2% -182.8% Higher ROE CGEN
52-Week Range Position Momentum 33% ($1โ€“$3) 9% ($0โ€“$1) Stronger Trend CGEN
Beta / 30D Volatility Risk Regime 1.44ฮฒ ยท 62% Vol 1.37ฮฒ ยท 138% Vol Lower Realized Risk CGEN
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite CGEN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEN vs EVGN Buy Guide
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EVGN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EVGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEN nor EVGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.